[Articles] Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
December 2, 2018
- The Lancet 392, 10161 (2018)
Author: Erin A Bohula, Benjamin M Scirica, Silvio E Inzucchi, Darren K McGuire, Anthony C Keech, Steven R Smith, Estella Kanevsky, Sabina A Murphy, Lawrence A Leiter, Jamie P Dwyer, Ramon Corbalan, Christian Hamm, Lee Kaplan, Jose Carlos Nicolau, Ton Oude Ophuis, Kausik K Ray, Mikhail Ruda, Jindrich Spinar, Tushar Patel, Wenfeng Miao, Carlos Perdomo, Bruce Francis, Shobha Dhadda, Marc P Bonaca, Christian T Ruff, Marc S Sabatine, Stephen D Wiviott, CAMELLIA-TIMI 61 Steering Committee Investigators
Lorcaserin decreases risk for incident diabetes, induces remission of hyperglycaemia, and reduces the risk of microvascular complications in obese and overweight patients, supporting the role of lorcaserin as an adjunct to lifestyle modification for chronic management of weight and metabolic health.